Ankylosing Spondylitis
📧 Sign up to get email alerts when something new happens for Ankylosing Spondylitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-09-15FDA Approved: CELECOXIB — Supplemental Application (Westminster Pharmaceuticals, LLC)
The FDA approved a supplemental application for a generic celecoxib product from Westminster Pharmaceuticals, expanding access under ANDA210…
-
FDA approval · 2022-09-06FDA Approved: NAPROXEN SODIUM — Supplemental Application (CVS)
The FDA approved a supplemental application for naproxen sodium sponsored by CVS.
-
FDA approval · 2022-07-18FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
The FDA approved Sandoz's supplemental application for the adalimumab biosimilar ADALIMUMAB-ADAZ. The approval covers multiple inflammatory …
-
FDA approval · 2022-06-17FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
The FDA approved a supplemental application for Enbrel (etanercept) from Immunex Corporation, resulting in labeling changes for the product.…
-
FDA approval · 2022-06-07FDA Approved: NAPROXEN — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber's naproxen generic original application for Naproxen. This generic NSAID is approved for relief of pain and inflammation…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-05-06FDA Approved: DICLOFENAC SODIUM — Original Application (Apotex Corp.)
FDA approved Apotex Corp's original application for diclofenac sodium tablets, a generic NSAID. This approval enables Apotex to market a gen…
-
CLINICAL_TRIALS trial_result · 2022-04-08Clinical Trial Update: Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis [Phase 4]
Phase 4 trial comparing 300 mg vs 150 mg secukinumab after escalation to 300 mg in Ankylosing Spondylitis; results posted in 2022.
-
FDA approval · 2022-03-11FDA Approved: NAPROXEN — Supplemental Application (Granules India Ltd)
FDA approved a supplemental application for naproxen sodium granules from Granules India Ltd, resulting in an approved supplemental request …
-
FDA approval · 2022-03-09FDA Approved: CELECOXIB — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for Celecoxib from Micro Labs Limited under an ANDA.
-
FDA approval · 2022-02-08FDA Approved: PIROXICAM — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for Piroxicam submitted by Teva Pharmaceuticals USA, Inc.
-
CLINICAL_TRIALS trial_result · 2022-01-27Clinical Trial Update: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS [Phase 2]
A Phase 2 clinical trial assessing preliminary efficacy, safety, and pharmacokinetics of subcutaneous JS005 in Chinese adults with active an…
-
FDA approval · 2022-01-11FDA Approved: CELECOXIB — Supplemental Application (NIVAGEN PHARMACEUTICALS, INC.)
The FDA approved a supplemental application for Celecoxib submitted by NIVAGEN Pharmaceuticals, Inc., for a generic Celecoxib product.
-
FDA approval · 2022-01-07FDA Approved: MELOXICAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for MELOXICAM (meloxicam) from Aurobindo Pharma Limited.
-
FDA approval · 2022-01-05FDA Approved: CELECOXIB — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for a generic celecoxib product (Celecoxib) under ANDA 202240.
-
CLINICAL_TRIALS trial_result · 2021-12-20Clinical Trial Update: REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) [Phase 4]
A Phase 4 clinical trial evaluating a reduced dose of a TNF inhibitor in patients with ankylosing spondylitis and axial spondyloarthritis; s…
-
FDA approval · 2021-12-17FDA Approved: YUSIMRY — Original Application (Coherus BioSciences Inc)
FDA approved YUSIMRY (adalimumab-aqvh) from Coherus BioSciences in an original biologics license application, likely as a biosimilar to adal…
-
CLINICAL_TRIALS trial_result · 2021-11-23Clinical Trial Update: Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) [Phase 2]
Phase 2 trial assessing safety and effectiveness of the Live Zoster Vaccine in patients using anti-TNF therapy for inflammatory diseases, wi…
-
CLINICAL_TRIALS trial_result · 2021-11-01Clinical Trial Update: Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis [Phase 2]
Phase 2 trial evaluating multiple subcutaneous doses of BCD-085 in active ankylosing spondylitis has completed.
-
CLINICAL_TRIALS trial_result · 2021-10-28Clinical Trial Update: Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis
A completed clinical trial evaluating the impact of early initiation of biological treatment for Ankylosing Spondylitis, with results posted…
-
FDA approval · 2021-10-15FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approves a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADBM from Quallent Pharmaceuticals Health LLC. The approval…
-
CLINICAL_TRIALS trial_result · 2021-07-20Clinical Trial Update: Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases [Phase 2]
Phase 2 clinical trial evaluating low-dose IL-2 to induce regulatory T cells in various autoimmune and inflammatory diseases; trial complete…
-
FDA approval · 2021-07-15FDA Approved: DICLOFENAC SODIUM/MISOPROSTOL DICLOFENAC-SODIUM-MISOPROSTOL — Original Application (Micro Labs Limited)
FDA approved the original application for a generic fixed-dose combination of diclofenac sodium and misoprostol from Micro Labs Limited.
-
CLINICAL_TRIALS trial_result · 2021-06-24Clinical Trial Update: Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis [Phase 2]
Phase 2 clinical trial assessing safety and tolerability of AIN457 in adults with moderate to severe ankylosing spondylitis has been complet…
-
CLINICAL_TRIALS trial_result · 2021-06-22Clinical Trial Update: Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS). [Phase 4]
Phase 4 trial update on the efficacy and safety of Yuxuebi Tablet for ankylosing spondylitis, with current status not specified.
-
FDA approval · 2021-06-17FDA Approved: INFLECTRA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves a supplemental application for INFLECTRA (infliximab-dyyb) from Pfizer Laboratories Div Pfizer Inc, marking FDA action on a bio…